Knowledge Partner Session 03: How Ethical Maturity Drives Economic Advantage: New Learnings from Healthcare
Mar 24, 2026 | 9:30 AM - 11:00 AM
Auditorium
Description
Organised by International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Integrity is increasingly recognized as a core driver of competitiveness in regulated and trust-dependent markets, shaping trade, investment, and supply-chain resilience. Drawing on new global research from Deepening the Value of Business Ethics for SMEs (2025), this session examines how ethics maturity functions as economic infrastructure - reducing transaction costs, strengthening regulatory performance, and enabling market access. Utilizing health-related sectors as a innovative use case, the research reveals how integrity mechanisms are embedded and scaled across complex systems through industry associations, multinational standards, and partner networks, generating measurable economic advantage for small and medium-sized enterprises. A senior, multi-stakeholder panel from industry, multilateral institutions, and civil society will explore the policy and ecosystem levers surfacing from new research that allow integrity to deliver sustainable growth, resilient supply chains, and long-term global prosperity for all sectors and stakeholders.
SPEAKERS:
- Sofie Melis, Director of Ethics & Compliance and Culture, IFPMA
- Dirk Brinckman, Chief Compliance Officer, Johnson & Johnson; Chair, Ethics and Business Integrity Committee and Chief Ethics and Compliance Officers Roundtable, IFPMA
- Noah Arshinoff, Faculty of Law, University of Ottawa; APEC Research Author
- Sobia Akram, Corporate Vice President, Global Business Ethics Compliance Office & Programme at Novo Nordisk
- Dani Mothci, Chief Executive Officer, International Alliance of Patients' Organizations
- Lisa Miller, Integrity Compliance Officer, The World Bank Group
This session is led by partner organisations and may not reflect the views of the OECD.
